Orlistat 1 A Pharma

Orlistat, the active ingredient in Orlistat 1 A Pharma, is a lipase inhibitor presented as a 1 mg oral capsule for oral use. It treats obesity by reducing dietary fat absorption in adults with a body mass index ≥ 30 kg/m², or ≥ 27 kg/m² with weight‑related comorbidities. GNH USA supplies Orlistat 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orlistat 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orlistat is indicated for the management of obesity and related metabolic conditions. - Obesity: helps achieve weight loss when combined with a reduced‑calorie, low‑fat diet. - Overweight with comorbidities: supports weight reduction in patients with a BMI ≥ 27 kg/m² who have hypertension, dyslipidaemia, or type 2 diabetes. - Weight‑maintenance after loss: aids in maintaining weight loss achieved through diet and lifestyle changes. - Prevention of weight‑gain associated with antipsychotic therapy: may limit weight increase in patients receiving certain psychiatric medications. - Adjunct to lifestyle therapy in metabolic syndrome: contributes to overall risk‑factor improvement when used with diet and exercise.

Orlistat may cause a range of gastrointestinal and systemic reactions.

Common Side Effects: - Oily spotting: oily droplets on under‑clothing or skin. - Fecal urgency: sudden need to defecate. - Fatty/oily stool: pale, greasy, foul‑smelling stools. - Flatulence with discharge: increased gas and possible oily discharge. - Abdominal cramping: intermittent stomach pain. - Reduced absorption of fat‑soluble vitamins: lower levels of vitamins A, D, E, K.

Serious or Rare Side Effects: - Acute liver injury: sudden onset of jaundice or elevated liver enzymes. - Severe allergic reaction: rash, itching, swelling, dizziness, or trouble breathing. - Pancreatitis: intense abdominal pain radiating to the back. - Kidney stones: flank pain, blood in urine, or urinary obstruction. - Persistent diarrhea: watery stools lasting more than two weeks. - Unexplained weight loss: rapid loss not related to diet changes.

Orlistat should be used with caution and under medical supervision. - Assess BMI: confirm patient meets BMI criteria before initiating therapy. - Monitor vitamin levels: supplement fat‑soluble vitamins (A, D, E, K) regularly. - Review concomitant medications: evaluate for drugs that require fat‑based absorption. - Counsel on low‑fat diet: advise patients to limit dietary fat to ≤30 g per day. - Observe for liver function changes: periodic liver enzyme testing is advisable. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Orlistat can interact with several medicines, affecting their absorption or efficacy.

Major Interactions (Avoid): - Cytochrome P450 inhibitors: may increase systemic exposure of co‑administered drugs. - Warfarin: reduced vitamin K absorption can alter anticoagulant effect. - Levothyroxine: decreased absorption may require dose adjustment.

Moderate Interactions (Monitor Closely): - Fat‑soluble vitamin supplements: timing must be separated by at least 2 hours. - Orph or  ");